CIK 0001374339 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
ProMIS Neurosciences Inc.
Sign in to watch- Ticker
- PMN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- 416-847-6898
- Business address
- SUITE 200, 1920 YONGE STREET, TORONTO, Ontario, Canada, M4S 3E2
- Former names
- AMORFIX LIFE SCIENCES LTD
- Open-market buys, last 90 days
- $134,746
- in 3 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$134,746. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-31 | Sclar Jeremy M. 10% owner | Purchase · Tranche C Common Share Purchase Warrants | +697,674 | 697,674 | ||
| 2024-07-31 | Sclar Jeremy M. 10% owner | Conversion · Series 2 Preferred Shares, no par value | −150,000 | 0 | ||
| 2024-07-31 | Sclar Jeremy M. 10% owner | Conversion · Series 2 Preferred Shares, no par value | −150,000 | 0 | ||
| 2024-01-02 | Warma Neil K Chief Executive Officer | Grant or award · Option (right to buy) | +200,000 | 208,333 | ||
| 2023-12-04 | Sclar Jeremy M. 10% owner | Sale · Series 1 Preferred Shares, no par value | −150,000 | 0 | ||
| 2023-12-04 | Sclar Jeremy M. 10% owner | Purchase · Series 2 Preferred Shares, no par value | +150,000 | 150,000 | ||
| 2023-12-04 | Sclar Jeremy M. 10% owner | Sale · Series 1 Preferred Shares, no par value | −150,000 | 0 | ||
| 2023-12-04 | Sclar Jeremy M. 10% owner | Purchase · Series 2 Preferred Shares, no par value | +150,000 | 150,000 | ||
| 2023-10-26 | Malenfant Gavin T. Chief Operating Officer | Grant or award · Option (right to buy) | +12,500 | 12,500 | ||
| 2023-10-26 | Kaplan Johanne Chief Development Officer | Grant or award · Option (right to buy) | +12,500 | 12,500 | ||
| 2023-10-26 | ALTSTIEL LARRY DOUGLAS Chief Medical Officer | Grant or award · Option (right to buy) | +12,500 | 12,500 | ||
| 2023-10-26 | Milbury Max A. Principal Accounting Officer | Grant or award · Option (right to buy) | +12,500 | 12,500 | ||
| 2023-10-26 | Cashman Neil Chief Scientific Officer | Grant or award · Option (right to buy) | +12,500 | 12,500 | ||
| 2023-10-26 | Geffken Daniel E. Chief Financial Officer | Grant or award · Option (right to buy) | +2,500 | 2,500 | ||
| 2023-08-23 | Farfel Gail M Chief Executive Officer | Grant or award | +53,192 | 55,192 | ||
| 2023-08-23 | Farfel Gail M Chief Executive Officer | Grant or award · Warrants to purchase Common Shares | +53,192 | 53,192 | ||
| 2023-08-23 | Malenfant Gavin T. Chief Operating Officer | Grant or award | +2,660 | 2,660 | ||
| 2023-08-23 | Malenfant Gavin T. Chief Operating Officer | Grant or award · Warrants to purchase Common Shares | +2,660 | 2,660 | ||
| 2023-08-23 | Cashman Neil Chief Scientific Officer | Grant or award | +10,643 | 113,304 | ||
| 2023-08-23 | Cashman Neil Chief Scientific Officer | Grant or award · Warrants to purchase Common Shares | +10,643 | 10,643 |
Page 7 of 8 · 158 trades